医学
红细胞分布宽度
内科学
急性冠脉综合征
心肌梗塞
冠状动脉监护室
心脏病学
人口
生物标志物
接收机工作特性
环境卫生
化学
生物化学
作者
Albert Sudharsono,Dina Khairina,Akhtar Fajar Muzakkir,Abdul Hakim Alkatiri,Muzakkir Amir
标识
DOI:10.1093/ehjci/ehaa946.1357
摘要
Abstract Introduction Red Blood Cell Distribution Width (RDW CV) and Plateletcrit (PCT) are part of complete blood count (CBC) examination. There are few studies have been reported the use of these parameters to predict clinical outcome including mortality, but none of them conducted in Asian population. We seek to investigate the role of PCT and RDW CV as a potential objective biomarker to predict in hospital mortality coincide with Global Registry of Acute Cardiac Events (GRACE) score in Acute Coronary Syndrome (ACS). Methods We respectively analysed patients with ACS who were admitted to the coronary care unit between June 2018 and December 2019. The GRACE and CBC were taken consecutively. Results A total of 1053 patients with ACS (46% non-ST elevated ACS (NSTE-ACS) and 54% ST elevated myocardial infarction (STEMI)] were enrolled in this study. PCT and RDW-CV was found to be significantly correlated with mortality (p<0.001). Further analysis showed significant higher level of PCT in patients with event compared to the other group (0.32 vs 0.24, p<0.001). Similar result was found for RDW (14.1 vs 13.2, p<0.001). ROC curve analysis for PCT and RDW-CV levels showed an AUC of 0.65, (cut off value: 0.25. p<0.001) and 0.69 (cut off value 13.05, p<0.001), respectively. High PCT and RDW-CV level were found to be a good predictor of mortality in ACS patients. (OR 2.6 and OR 3.4 respectively, p<0.001) In patients with high risk GRACE risk categories, we found a significantly higher levels of PCT (0.27 vs 0.24, p<0.001) and RDW-CV (13.8 vs 13.2, p<0.001) compared to low-intermediate risk group. Conclusion(s) We found that both PCT and RDW-CV may act as novel and promising tool to predict in hospital mortality directly proportional with GRACE Score among ACS patient. Figure 1. ROC curve for PCT and RDW-CV. Funding Acknowledgement Type of funding source: None
科研通智能强力驱动
Strongly Powered by AbleSci AI